2 Part, Phase II Study of Intravenous, Single Ascending Dose Administrations of IOP Injection in Patients With Iron Deficient Anemia
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Iron oxide-PEG (Primary) ; Dextran sulfate
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors Megapro Biomedical Company
- 21 Nov 2018 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 21 Nov 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.